YD BioYDES +4.69%12 EBITDA Margin % is -1,392.29% as of Dec. 2025. GuruFocus rates YDES with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, YD Bio ranks worse than 82.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. YD Bio's EBITDA for the
six
months ended in Dec. 2025 was $-8.31 Mil. YD Bio's Revenue for the
six
months ended in Dec. 2025 was $0.60 Mil. Therefore, YD Bio's EBITDA margin for the quarter that ended in Dec. 2025 was -1,392.29%.
YD Bio (NAS:YDES) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
YD Bio EBITDA Margin % Related Terms
YD Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for YD Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio EBITDA Margin % Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
6.29
-251.18
-1,357.29
YD Bio Semi-Annual Data
Dec24
Jun25
Dec25
EBITDA Margin %
0.00
0.00
-1,392.29
YDES vs CRBU, ABOS, PRQR: EBITDA Margin % Comparison
For the Biotechnology subindustry, YD Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where YD Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio (YDES) has a EBITDA Margin % of -1,392.29% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on YD Bio and its competitors. According to the industry distribution chart, YD Bio ranks #778 out of 939 companies in the Biotechnology industry, placing it in the top 82.9%.
Is YD Bio's EBITDA Margin % too high?
YD Bio's current EBITDA Margin % is -1,392.29%. Based on the distribution chart, YD Bio ranks #778 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's EBITDA Margin % compare to CRBU and ABOS?
According to the Biotechnology industry distribution chart, YD Bio ranks #778 out of 939 companies for EBITDA Margin %. This places YD Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on YD Bio and its competitors. YD Bio's current EBITDA Margin % is -1,392.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current EBITDA Margin % of -1,392.29%. The current EBITDA Margin % is -1,392.29%. YD Bio's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For YD Bio (YDES), the current EBITDA Margin % is -1,392.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score
Get the complete analysis for YDES
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 